Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersInfectious Disease Physician in Chicago, IL
NPI: 1093776460Primary Practice Location
RUSH UNIVERSITY MEDICAL CENTER
1620 W Harrison St, Chicago, IL
Primary Employer
Rush University Internists
rush.edu
HQ Phone
Get M.D. Beverly's Phone Numberphone_androidMobile
Get M.D. Beverly's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
IL State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 48 | 68 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 35 | 54 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 22 | 35 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 17 | 26 |
| 5 | 99223Initial hospital inpatient care, typically 70 minutes per day | 13 | 14 |
Authors: Pablo Tebas, Markella Zanni, Samuel Schnittman, Carlos Malvestutto, Carl Fichtenbaum, Judith Aberg, Kristine Erlandson, Judith Currier, Steven Grinspoon
Journal: Clin Infect Dis
Acupuncture to Reduce HIV-Associated Inflammation.
Authors: Barbara Swanson, Joyce Keithley, Angela Johnson, Louis Fogg, Oluwatoyin Adeyemi, Beverly Sha, Kimberly Snell
Publication Date: 2015-02-12
Authors: Moira Mcnulty, Nancy Glick, Richard Novak, David Pitrak, Arthur Moswin, Janet Lin
Journal: J Int Assoc Provid AIDS Care
Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Intervention / Treatment: DRUG: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Intervention / Treatment: DRUG: Sofosbuvir/Velpatasvir (SOF/VEL), OTHER: Minimal Monitoring (MINMON) Strategy
Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), Exegi Pharma, LLC
Intervention / Treatment: DRUG: Placebo, DRUG: Visbiome Extra Strength
